Last reviewed · How we verify
NCT05574166
A Phase I Study to Evaluate Safety and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8356
Phase 1 trial testing SP-8356 in Atherosclerosis in 31 participants. Terminated before completion.
28 October 2021
Quick facts
| Lead sponsor | Shin Poong Pharmaceutical Co. Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 31 |
| Start date | 3 January 2021 |
| Primary completion | 28 October 2021 |
| Estimated completion | 29 October 2021 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- SP-8356 — full drug profile →
- Placebo
Conditions studied
- Atherosclerosis — all drugs for Atherosclerosis →
- Ischemic Stroke — all drugs for Ischemic Stroke →
Sponsor
Shin Poong Pharmaceutical Co. Ltd. — full company profile →
Who can join
Adults 18 to 55, male only, with Atherosclerosis or Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a 2-part, single-centre, randomised study in healthy males. Part 1 is a double-blind, randomised, placebo-controlled, single ascending dose (SAD) study in healthy males. Part 2 is a double-blind, randomised, placebo-controlled, multiple ascending dose (MAD) study in healthy males.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target.
Yang XM, Bian H, Chen ZN. · · 2026 · cited 1× · PMID 41454696 · DOI 10.1002/advs.202518884
Verify or expand the search:
- PubMed search for NCT05574166
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atherosclerosis
Currently open trials in the same condition.
- NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT06788431 — A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary · EARLY_PHASE1 · recruiting
- NCT06676046 — Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions · recruiting
- NCT06694012 — Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2 · recruiting
Other Shin Poong Pharmaceutical Co. Ltd. trials
Trials by the same sponsor.
- NCT06660719 — Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of · Phase 3 · recruiting
- NCT07064525 — Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension · Phase 2 · enrolling by invitation
- NCT06826872 — Efficacy and Safety of SPC1001 in Patients With Essential Hypertension · Phase 2 · recruiting
- NCT05633420 — Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients · Phase 2 · completed
- NCT06212648 — Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05574166 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shin Poong Pharmaceutical Co. Ltd.
- Last refreshed: 10 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05574166.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing